OCEANSIDE, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced today the signing of an agreement between TSOI and Jadi Cell LLC for licensing of the Jadi Cell universal donor adult stem cell, as covered in US Patent No.: 9,803,176 B2 for use in Chronic Traumatic Encephalopathy (CTE), and Traumatic Brain Injury (TBI).
The Jadi Cell product, which belongs to the mesenchymal stem cell (MSC) family of cells, is a unique adult stem cell, which produces higher levels of therapeutic factors compared to other stem cells. The cells have demonstrated safety in animal models and pilot human trials. The Jadi Cell product is generated from umbilical cords, which are a source of medical waste and available in large quantities at inexpensive prices.
Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe.
Traumatic brain injury (TBI) is an insult to the brain, not of a degenerative or congenital nature, but caused by external physical force that may produce a diminished or altered state of consciousness, which results in an impairment of cognitive abilities or physical functioning.
"The team assembled by Mr. Dixon is not only impressive, but has succeeded in developing, patenting, and commercializing regenerative and immunological based approaches to a variety of chronic conditions1,2," said Dr. Amit Patel. "CTE represents a significant unmet medical need which we believe is amenable to stem cell intervention. We are eager to work with Mr. Dixon and his internationally renowned team in accelerating treatments and potential cures for debilitating conditions such as CTE and traumatic brain injury."
"Many of my colleagues suffer from CTE. At present there are no therapeutic approaches that possess even the potential to reverse this terrible condition. The cells developed by Dr. Amit Patel, for the first time, give me hope that a treatment may be possible," said Wes Chandler, former NFL Player of 11 seasons.
"It is my honor to work with Dr. Amit Patel, who has a track record of successful FDA applications and product development in the area of regenerative medicine, to accelerate clinical translation of this new treatment modality for patients suffering from brain injuries," said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. "We plan to leverage New regulatory pathways such as the recently approved "Right to Try" Law to deliver these medicines as soon as possible to patients which currently have no other options."
"We are especially enthusiastic about clinically developing the Jadi Cell product because of its advanced stage of development," said Timothy Dixon, President and CEO of TSOI. "In contrast to other stem cell types, which require years, if not decades of development before entry into American patients, we believe that we will be treating patients within 12 months. Currently means of isolating, producing, scaling up, and delivery of the cells has all been worked out by Dr. Patel and Collaborators. We are confident that coming from this position of strength, we will be positioned ahead of everyone in the area of regenerative medicine focusing on CTE."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Therapeutic Solutions International, Inc.